- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01262976
Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults
Safety and Immunogenicity of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to HIV-positive Adults Living in a Tuberculosis Endemic Region
The purpose of the study is to assess the safety and immunogenicity of a GlaxoSmithKline (GSK) Biologicals' candidate tuberculosis vaccine (692342) administered to Human Immunodeficiency Virus (HIV)-positive adults aged 18 to 59 years, living in a tuberculosis endemic region.
Subjects will be followed-up for 3 years.
Subjects will be enrolled in 3 cohorts:
- HIV-positive adults on highly active antiretroviral therapy
- HIV-positive adults not on highly active antiretroviral therapy
- HIV-negative adults
Each cohort will have 2 groups.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
-
Tharamani Chennai, India, 600113
- GSK Investigational Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
- A male or female between, and including, 18 and 59 years of age at the time of the first vaccination.
- Written informed consent obtained from the subject prior to any study procedure.
- Female subjects of non-childbearing potential may be enrolled in the study.
Female subjects of childbearing potential may be enrolled in the study, if the subject:
- has practiced adequate contraception for 30 days prior to vaccination,
- has a negative pregnancy test on the day of vaccination, and
- has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.
- Clinically acceptable laboratory values at screening as determined by the investigator.
- No evidence of tuberculosis disease with no evidence of pulmonary pathology as confirmed by chest X-ray.
- No history of extra pulmonary tuberculosis.
- Based on their medical history, all subjects must have no history of chemotherapy for tuberculosis.
Additional inclusion criteria for subjects to be enrolled in HIV+ on highly active antiretroviral therapy cohort:
- Subjects must be HIV-positive and under care of a physician for at least 6 months.
- Subjects must have a CD4+T cell count >= 250 cells/mm3 at screening.
- Subjects must be stable on highly active antiretroviral therapy for at least 6 months, with an undetectable HIV viral load level at screening.
Additional inclusion criteria for subjects to be enrolled in HIV+ treatment naïve cohort:
- Subjects must be HIV-positive and under care of a physician for at least 6 months
- Subjects must be highly active antiretroviral therapy-naïve (never received anti-retroviral therapy after HIV diagnosis)
- Subjects must have a CD4 + T cell count above 350 cells/mm3 at screening.
- Subjects for whom commencement of highly active antiretroviral therapy is not expected based on current assessment within next year.
- Subjects must have a viral load between 5000 - 80000 copies/mL at screening.
Additional inclusion criteria for subjects to be enrolled in HIV-negative cohort
• Subjects must be negative for HIV-1.
Exclusion Criteria:
- Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- Administration of a registered live vaccine not foreseen by the study within 30 days preceding the first dose of study vaccine and administration of a registered inactivated vaccine within 14 days preceding the first dose of study vaccine.
- History of previous administration of experimental Mtb vaccines.
- History of previous exposure to components of the investigational vaccine within 30 days preceding the first dose of study vaccine
- Chronic administration of immunosuppressant or other immune-modifying drugs within six months prior to the first vaccine/product dose. For corticosteroids, this will mean prednisone >= 20 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.
- Any condition or illness or medication, which in the opinion of the Investigator might interfere with the evaluation of the safety or immunogenicity of the vaccine.
- Planned participation or participation in another experimental protocol with an experimental product during the study period.
- Administration of any immunoglobulin, any immunotherapy and/or any blood products within the three months preceding the first dose of study vaccination, or planned administrations during the study period.
- Subjects taking any of the following medication: chronic administration of systemic steroids, interleukins, systemic interferon or systemic chemotherapy.
- History of allergic reactions or anaphylaxis to any drug or vaccine.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- History of chronic alcohol consumption and/or drug abuse which in the Investigator's opinion would put the subject at risk.
- Pregnant female, lactating female or female planning to become pregnant or stop contraception.
- Acute or chronic clinically relevant pulmonary, cardiovascular, hepatic or renal function abnormality as determined by physical examination or laboratory screening tests.
Additional exclusion criteria for subjects to be enrolled in HIV+ on highly active antiretroviral therapy cohort:
- Any change in anti-retroviral drug regimen within 12 weeks prior to screening.
- Any chronic drug therapy, other than highly active antiretroviral therapy or prophylaxis for opportunistic HIV related infections, birth control pills, anti-histamines for seasonal allergies and SSRIs.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: HIV(+)-HA/GSK692342
HIV-infected subjects between and including 18 to 59 years of age, who were on Highly Active Anti-Retroviral Therapy (HAART) at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
|
Intramuscular, 2 doses
|
Placebo komparator: HIV(+)-HA/Placebo
HIV-infected subjects between and including 18 to 59 years of age, who were on Highly Active Anti-Retroviral Therapy (HAART) at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
|
Intramuscular, 2 doses
|
Eksperimentell: HIV(+)-TN/GSK692342
HIV-infected subjects between and including 18 to 59 years of age, who were HAART-treatment naive (TN) at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
|
Intramuscular, 2 doses
|
Placebo komparator: HIV(+)-TN/Placebo
HIV-infected subjects between and including 18 to 59 years of age, who were HAART-treatment naive (TN) at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
|
Intramuscular, 2 doses
|
Eksperimentell: HIV(-)/GSK692342
Subjects between and including 18 to 59 years of age, who were HIV-negative at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
|
Intramuscular, 2 doses
|
Placebo komparator: HIV(-)/Placebo
Subjects between and including 18 to 59 years of age, who were HIV-negative at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
|
Intramuscular, 2 doses
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of Subjects With Grade 3 Solicited Local Symptoms
Tidsramme: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
|
Solicited local symptoms assessed were pain and swelling.
Grade 3 pain = pain that prevented normal activity.
Grade 3 swelling = swelling spreading beyond 50 millimeters (mm) of injection site.
|
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
|
Number of Subjects With Grade 3 Solicited General Symptoms
Tidsramme: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
|
Solicited general symptoms assessed were fatigue, temperature [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)], gastrointestinal symptoms (gastro) [nausea, vomiting, diarrhoea and/or abdominal pain], headache, malaise and myalgia.
Grade 3 symptom = symptom that prevented normal activity.
Grade 3 fever = fever ≥ 39.5 °C.
|
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
|
Number of Subjects With Grade 3 Unsolicited Adverse Events (AEs)
Tidsramme: During the 30-day (Days 0-29) post-vaccination period
|
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset out-side the specified period of follow-up for solicited symptoms.
Grade 3 AE = an AE which prevented normal, everyday activities.
|
During the 30-day (Days 0-29) post-vaccination period
|
Number of Subjects With Serious Adverse Events (SAEs)
Tidsramme: From screening up to one month post Dose 2
|
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
|
From screening up to one month post Dose 2
|
Number of Subjects With Grade 3 and Grade 4 Haematological and Biochemical Levels
Tidsramme: At Day 0
|
Haematological and biochemical parameters assessed were haemoglobin [Hgb], white blood cells [WBC], platelets [PLA], alanine aminotransferase [ALT], aspartate aminotransferase [AST] and creatinine [CREA].
The haematology and biochemistry toxicity grading scale was based on the Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.
|
At Day 0
|
Number of Subjects With Grade 3 and 4 Haematological and Biochemical Levels
Tidsramme: At Day 7
|
Haematological and biochemical parameters assessed were haemoglobin [Hgb], white blood cells [WBC], platelets [PLA], alanine aminotransferase [ALT], aspartate aminotransferase [AST] and creatinine [CREA].
The haematology and biochemistry toxicity grading scale was based on the Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.
|
At Day 7
|
Number of Subjects With Grade 3 and Grade 4 Haematological/Biochemical Levels
Tidsramme: At Day 30
|
Haematological and biochemical parameters assessed were haemoglobin [Hgb], white blood cells [WBC], platelets [PLA], alanine aminotransferase [ALT], aspartate aminotransferase [AST] and creatinine [CREA].
The haematology and biochemistry toxicity grading scale was based on the Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.
|
At Day 30
|
Number of Subjects With Grade 3-4 Haematological and Biochemical Levels
Tidsramme: At Day 37
|
Haematological and biochemical parameters assessed were haemoglobin [Hgb], white blood cells [WBC], platelets [PLA], alanine aminotransferase [ALT], aspartate aminotransferase [AST] and creatinine [CREA].
The haematology and biochemistry toxicity grading scale was based on the Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.
|
At Day 37
|
Number of Subjects With Grade 3-4 Haematological/Biochemical Levels
Tidsramme: At Day 60
|
Haematological and biochemical parameters assessed were haemoglobin [Hgb], white blood cells [WBC], platelets [PLA], alanine aminotransferase [ALT], aspartate aminotransferase [AST] and creatinine [CREA].
The haematology and biochemistry toxicity grading scale was based on the Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.
|
At Day 60
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Antall emner med eventuelle uønskede AE
Tidsramme: I løpet av 30 dager (dager 0-29) etter vaksinasjon
|
En uønsket bivirkning dekker enhver uønsket medisinsk hendelse i et klinisk undersøkelsesobjekt som er midlertidig assosiert med bruken av et legemiddel, enten det anses relatert til legemidlet eller ikke og rapporteres i tillegg til de som ble bedt om under den kliniske studien og ethvert ønsket symptom med utbrudd utenfor den angitte perioden for oppfølging av etterspurte symptomer.
Enhver ble definert som forekomsten av enhver uønsket bivirkning uavhengig av intensitetsgrad eller relasjon til vaksinasjon.
|
I løpet av 30 dager (dager 0-29) etter vaksinasjon
|
Anti-Mycobacterium Tuberculosis Fusion Protein (M72) Specific Antibody Concentrations
Tidsramme: At Days 0, 30, 60, 210 and at Years 1, 2 and 3
|
Concentration of M72-specific antibodies, as measured by the enzyme-linked immunosorbent assay (ELISA), were given in ELISA units per milliliter (EU/mL) and expressed as geometric mean concentrations (GMCs).
|
At Days 0, 30, 60, 210 and at Years 1, 2 and 3
|
Number of Seroconverted Subjects for M72-specific Antibodies
Tidsramme: At Days 0, 30, 60, 210 and at Years 1, 2 and 3
|
A seroconverted subject for M72 antibodies was defined as a seronegative subject at baseline, with the appearance of M72 antibody concentration higher than or equal to (≥) the cut-off value of 2.8 EL.U/mL post vaccination.
Antibody concentrations below the cut-off value of the assay were given an arbitrary value of half the cut-off value for the purpose of GMC calculation.
|
At Days 0, 30, 60, 210 and at Years 1, 2 and 3
|
Frequency of M72-cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Immune Markers
Tidsramme: At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
|
Among immune markers expressed after background reduction were interleukin-2 (IL-2), interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α) and cluster of differentiation 40 - ligand (CD40-L).
This endpoint presents results for CD4-all doubles.
|
At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
|
Frequency of M72-CD4+ T-cells Expressing Any Combination of Cytokines
Tidsramme: At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
|
Among cytokines expressed after background reduction were cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α).
This endpoint presents results for the following cytokine combinations: CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+), CD4.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-),CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+),CD4.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-),CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+).
|
At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
|
M72-cluster of Differentiation 4 (CD4+) T-cells Frequency Expressing Any Combination of Cytokines
Tidsramme: At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
|
Among cytokines expressed after background reduction were cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α).
This endpoint presents results for the following cytokine combination: CD4.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-), CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+),CD4.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+),CD4.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-)
|
At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
|
M72-CD4+ T-cells Frequency Expressing Any Combination of Cytokines
Tidsramme: At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
|
Among cytokines expressed after background reduction were cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α).
This endpoint presents results for the following cytokine combination: CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), CD4.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-),CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+),CD4.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-), CD4.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+).
|
At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
|
Frequency of M72-cluster of Differentiation 8 (CD8+) T-cells Expressing at Least 2 Immune Markers
Tidsramme: At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
|
Among immune markers expressed after background reduction were interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α).
This endpoint presents results for CD8-all doubles.
|
At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
|
Frequency of M72-CD8+ T-cells Expressing Any Combination of Cytokines
Tidsramme: At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
|
Among cytokines expressed after background reduction were cluster of differentiation 40-ligand (CD40-L) interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α).
This endpoint presents results for the following cytokine combination: CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(+),CD8.CD40L(+)+IL2(+)+TNFa(+)+IFNg(-),CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(+),CD8.CD40L(+)+IL2(+)+TNFa(-)+IFNg(-),CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(+).
|
At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
|
M72-cluster of Differentiation 8 (CD8+) T Frequency Cells Expressing Any Combination of Cytokines
Tidsramme: At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
|
Among cytokines expressed after background reduction were cluster of differentiation 40-ligand (CD40-L) interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α).
This endpoint presents results for the following cytokine combination: CD8.CD40L(+)+IL2(-)+TNFa(+)+IFNg(-),CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(+),CD8.CD40L(+)+IL2(-)+TNFa(-)+IFNg(-),CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(+),CD8.CD40L(-)+IL2(+)+TNFa(+)+IFNg(-).
|
At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
|
M72-CD8+ T-cells Frequency Expressing Any Combination of Cytokines
Tidsramme: At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
|
Among cytokines expressed after background reduction were cluster of differentiation 40-ligand (CD40-L) interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α).
This endpoint presents results for the following cytokine combination: CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(+), CD8.CD40L(-)+IL2(+)+TNFa(-)+IFNg(-),CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(+), CD8.CD40L(-)+IL2(-)+TNFa(+)+IFNg(-),CD8.CD40L(-)+IL2(-)+TNFa(-)+IFNg(+).
|
At Days 0, 7, 30, 37, 60, 210 and at Years 1, 2 and 3
|
Number of Subjects With Any Solicited Local Symptoms
Tidsramme: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
|
Solicited local symptoms assessed were pain and swelling.
Any = occurrence of the symptom regardless of intensity grade.
|
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
|
Number of Subjects With Any Solicited General Symptoms
Tidsramme: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
|
Solicited general symptoms assessed were fatigue, gastrointestinal symptoms (Gastro), headache, malaise, myalgia and temperature.
Any = occurrence of the symptom regardless of intensity grade.
|
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
|
Number of Subjects With SAEs
Tidsramme: From one month post Dose 2 up to study end (Year 3)
|
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
|
From one month post Dose 2 up to study end (Year 3)
|
Number of Subjects Presenting Different Grades of Haematological and Biochemical Values
Tidsramme: At Days 0, 7, 30, 37 and 60
|
Biochemical and haematological parameters included haemoglobin [Hgb], white blood cells [WBC], platelets [PLA], alanine aminotransferase [ALT], aspartate aminotransferase [AST] and creatinine [CREA].
Levels assessed were - normal, grade 1, grade 2 and missing grade.
The haematology and biochemistry toxicity grading scale was based on the Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.
|
At Days 0, 7, 30, 37 and 60
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 113935
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Tuberkulose
-
University Children's Hospital BaselUniversity Hospital, Geneva; University Hospital Inselspital, Berne; Kantonsspital... og andre samarbeidspartnereRekrutteringTuberkulose | Mycobacterium TuberculosisSveits
-
National Institute of Allergy and Infectious Diseases...FullførtMycobacterium TuberculosisBrasil
-
The University of Texas Health Science Center,...National Institute of Allergy and Infectious Diseases (NIAID)FullførtMycobacterium TuberculosisForente stater, Colombia, Mexico
-
Johns Hopkins UniversityAvsluttetMycobacterium TuberculosisForente stater
-
National Institute of Allergy and Infectious Diseases...Fullført
-
National Institute of Allergy and Infectious Diseases...Fullført
-
François SpertiniUniversity of OxfordFullførtTuberkulose | Mycobacterium Tuberculosis, beskyttelse motSveits
-
Region SkåneRekrutteringLatent tuberkulose | Mycobacterium Tuberculosis | Vedvarende infeksjonSverige
-
Serum Institute of India Pvt. Ltd.Vakzine Projekt Management GmbHAktiv, ikke rekrutterendeMycobacterium Tuberculosis-infeksjonGabon, Kenya, Sør-Afrika, Tanzania, Uganda
-
Johns Hopkins UniversityUnited States Agency for International Development (USAID)Har ikke rekruttert ennåTuberkulose | Tuberkulose, lunge | Mycobacterium Tuberculosis | Tuberkulose, lymfeknuteUganda, Sør-Afrika, Mosambik, Indonesia, Zambia